妇产与遗传（电子版）
婦產與遺傳（電子版）
부산여유전（전자판）
Obstetrics-Gynecology and Genetics(Electronic Edition)
2013年
4期
28-32
,共5页
雌二醇%绝经期%危险因素%心血管系统
雌二醇%絕經期%危險因素%心血管繫統
자이순%절경기%위험인소%심혈관계통
Estradiol%Menopause%Risk factors%Cardiovascular system
目的：对绝经早期妇女用雌二醇屈螺酮进行治疗，观察对心血管功能的影响。方法将42例绝经早期妇女分为两组。A组22例，每日服用雌二醇屈螺酮片1片，连续6个月；B组20例，每日碳酸钙D3片1片，连续6个月。用药前后测定体重指数（BMI）、绝经症状评分、缺血性心血管疾病（ICVD）10年发病危险度评估、踝肱指数（ABI）、空腹胰岛素、空腹血糖、总胆固醇、甘油三脂、高密度脂蛋白、低密度脂蛋白、雌二醇、总睾酮、抗凝血酶III。结果 A组治疗后绝经症状评分、ICVD评分降低，雌二醇升高，总睾酮下降，收缩压和总胆固醇下降，与治疗前相比有显著性差异（t=-13.432~8.015, P=0.000~0.042）；B组治疗后绝经症状评分和ICVD评分升高，与治疗前相比有显著性差异（t=-4.158~-3.476, P=0.003~0.029）。其余各项指标两组用药前后没有明显改变。结论绝经早期妇女使用雌二醇屈螺酮，可以缓解绝经相关症状，减少ICVD评分，降低收缩压，同时使总睾酮和总胆固醇下降，对心血管系统具有保护作用。
目的：對絕經早期婦女用雌二醇屈螺酮進行治療，觀察對心血管功能的影響。方法將42例絕經早期婦女分為兩組。A組22例，每日服用雌二醇屈螺酮片1片，連續6箇月；B組20例，每日碳痠鈣D3片1片，連續6箇月。用藥前後測定體重指數（BMI）、絕經癥狀評分、缺血性心血管疾病（ICVD）10年髮病危險度評估、踝肱指數（ABI）、空腹胰島素、空腹血糖、總膽固醇、甘油三脂、高密度脂蛋白、低密度脂蛋白、雌二醇、總睪酮、抗凝血酶III。結果 A組治療後絕經癥狀評分、ICVD評分降低，雌二醇升高，總睪酮下降，收縮壓和總膽固醇下降，與治療前相比有顯著性差異（t=-13.432~8.015, P=0.000~0.042）；B組治療後絕經癥狀評分和ICVD評分升高，與治療前相比有顯著性差異（t=-4.158~-3.476, P=0.003~0.029）。其餘各項指標兩組用藥前後沒有明顯改變。結論絕經早期婦女使用雌二醇屈螺酮，可以緩解絕經相關癥狀，減少ICVD評分，降低收縮壓，同時使總睪酮和總膽固醇下降，對心血管繫統具有保護作用。
목적：대절경조기부녀용자이순굴라동진행치료，관찰대심혈관공능적영향。방법장42례절경조기부녀분위량조。A조22례，매일복용자이순굴라동편1편，련속6개월；B조20례，매일탄산개D3편1편，련속6개월。용약전후측정체중지수（BMI）、절경증상평분、결혈성심혈관질병（ICVD）10년발병위험도평고、과굉지수（ABI）、공복이도소、공복혈당、총담고순、감유삼지、고밀도지단백、저밀도지단백、자이순、총고동、항응혈매III。결과 A조치료후절경증상평분、ICVD평분강저，자이순승고，총고동하강，수축압화총담고순하강，여치료전상비유현저성차이（t=-13.432~8.015, P=0.000~0.042）；B조치료후절경증상평분화ICVD평분승고，여치료전상비유현저성차이（t=-4.158~-3.476, P=0.003~0.029）。기여각항지표량조용약전후몰유명현개변。결론절경조기부녀사용자이순굴라동，가이완해절경상관증상，감소ICVD평분，강저수축압，동시사총고동화총담고순하강，대심혈관계통구유보호작용。
Objective To observe the effects of Estradiol Drospirenone on cardiovascular function in early postmenopausal women. Methods The 42 early postmenopausal women were divided into two groups. In group A 22 cases were taken Estradiol Drospirenone a tablet once a day for 6 months.In group B 20 cases were taken Calcium D3 a tablet once a day for 6 months. BMI, Menopausal Symptom Score, ICVD, ABI, blood pressure, fasting insulin, fasting glucose, total cholesterol, triglycerides, HDL, LDL, estradiol, total testosterone, antithrombin III were evaluated before and after therapy. Results In group A Menopausal Symptom Scores and ICVD were lower, estradiol was elevated and total testosterone was declined, systolic blood pressures and total cholesterol were decreased after therapy. There was a significant difference compared with before treatment(t=-13.432~8.015, P=0.000~0.042). In group B menopausal Symptom Scores and ICVD were elevated after therapy. There was a significant difference compared with before treatment (t=-4.158~-3.476, P=0.003~0.029). There was no significant change on the other of the indicators before and after treatment in these two groups. Conclusions In early postmenopausal women, Estradiol Drospirenone may relief the related symptoms of the menopause, decline the ICVD scores, reduce systolic blood pressure, decrease total testosterone and total cholesterol. It has been shown that Estradiol Drospirenone can protect cardiovascular function.
